GRI Bio, Inc.

Healthcare · Biotechnology · United States

Last price 1.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ...